MedTrace Logo

Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance -

NCT02106455 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 315

Last updated 2019-06-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of sodium risedronate tablets administered once daily (one tablet per dose) in patients with osseous Paget's disease for 48 weeks from baseline in daily medical practice.

Conditions

  • Osseous Paget's Disease

Interventions

DRUG

Sodium risedronate

Sodium risedronate tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-01
Primary Completion
2017-10-24
Completion
2017-10-24

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02106455 on ClinicalTrials.gov